

Taiwan Shilin District



Prosecutors office Press Release

(Abstract of the indictment)

Issue of date : 2024.05.14

Contact of Point : Deputy Chief Prosecutor

Chihming Chang

02-2836-1403

Prosecutors of Shihlin District Prosecutors Office indicted the insider trading case related to certain biopharma companies.

Abstract of the indictment as follows : Certain biopharma companies (hereby T Biopharm) negotiate with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on the purchase of BNT's COVID-19 vaccine and exchange views with the CDC of Taiwan on vaccine procurement in 2020. T Biopharm made major public announcements on October 12 after BNT sent a letter of authorization on October 9. Nevertheless, T Biopharm and the CDC of Taiwan could not reach a consensus on the quantity and price of vaccine purchases, so they terminated the discussion for vaccine authorization on November 3 of the same year and made

this major news public on the same day.

However, the defendant Shi-○○, the general manager of T Biopharm at the time, and others learned of the news that T Biopharm had a significant impact on its stock price, they took the opportunity to buy and sell warrants or stocks during the prohibited trading period, making a total illegal profit of more than NT\$4.13 million. They are all indicted for violating Article 171, Paragraph 1, of the Securities and Exchange Act. 1 count of insider trading.